

AMENDMENTS TO THE CLAIMS

1. (original) A preparation for facilitating site-specific gene conversion, comprising at least a collagen and an oligonucleotide for gene conversion.

2. (original) A preparation for site-specific gene therapy, comprising at least a collagen and an oligonucleotide for gene conversion.

3. (currently amended) The preparation according to claim 1 ~~or 2~~, wherein collagen is water-soluble collagen.

4. (original) The preparation according to claim 3, wherein the water-soluble collagen is atelocollagen.

5. (currently amended) The preparation according to any one of claims 1 to 4, 34 and 35, wherein the oligonucleotide for gene conversion is an oligonucleotide comprising of at least 20 bases.

6. (currently amended) The preparation according to ~~any one of claims 1 to 5~~ claim 1, wherein the oligonucleotide for gene conversion is a RNA/DNA chimeric oligonucleotide or a DNA oligonucleotide.

7. (currently amended) The preparation according to claim 5 ~~or 6~~, wherein the oligonucleotide for gene conversion is an oligonucleotide having a nucleotide sequence forming a Watson-Crick type base pair containing mismatch pairing of 1 to 3 base pairs, with a sense strand or an antisense strand of a gene to be converted.

8. (currently amended) The preparation according to claim 5 ~~or 6~~, wherein the oligonucleotide for gene conversion is an oligonucleotide having a nucleotide sequence forming

a Watson-Crick type base pair containing deletion or insertion of 1 to 3 bases, with a sense strand or an antisense strand of a gene to be converted.

9. (original) The preparation according to claim 7, wherein the mismatch pairing is located at a central part of an oligonucleotide.

10. (original) The preparation according to claim 8, wherein the deletion or insertion of bases is located at a central part of an oligonucleotide.

11. (currently amended) The preparation according to ~~any one of claims 1 to 10~~ claim 1 or 2, wherein a dosage form is solution-like.

12. (canceled)

13. (canceled)

14. (currently amended) The preparation according to ~~any one of claims 11 to 13~~ claim 11, wherein an oligonucleotide for gene conversion and a collagen form a particulate associated body.

15. (original) The preparation according to claim 14, wherein a long diameter of the particulate associated body is 300nm to 50 μ m.

16. (currently amended) The preparation according to ~~any one of claims 11 to 15~~ claim 11, which comprises collagen in a range of 0.01 to 1.0% by weight.

17. (canceled)

18. (original) A preparation for facilitating site-specific gene conversion or a preparation for gene therapy, obtained by dissolving collagen in a solution containing 0.01M to 0.1M of a phosphate salt and 0.07M to 0.14M of a sodium salt, adding an oligonucleotide solution for gene conversion containing the same concentration of a phosphate salt and the same concentration of a sodium salt thereto, and stirring this under a temperature of 1 to 10°C.

19. (currently amended) The preparation according to ~~any one of claims 1 to 10~~claim 1 or 2, wherein a dosage form is solid-like, and an oligonucleotide for gene conversion and a collagen form a particulate associated body.

20. (original) The preparation according to claim 19, wherein an oligonucleotide for gene conversion and a collagen form a particulate associated body.

21. (original) The preparation according to claim 20, wherein a long diameter of a particulate associated body is 300nm to 50µm.

22. (currently amended) A method of arbitrarily converting a specific base on a genome gene in a nucleus of a cell, which comprises contacting the preparation for facilitating gene conversion as defined in ~~any one of claims 1, and 3 to 21~~claim 1 or 3 with the cell.

23. (original) The method according to claim 22, wherein the cell is a mammal cell.

24. (original) The method according to claim 22, wherein the cell is yeast or fungus.

25. (original) A preparation for facilitating an oligonucleotide intranuclear localization in a nucleus, comprising at least a collagen and an oligonucleotide.

26. (canceled)

27. (canceled)

28. (currently amended) The preparation for facilitating intranuclear localization according to ~~any one of claims 25 to 27~~claim 25, wherein the oligonucleotide and the collagen form a particulate associated body.

29. (original) The preparation for facilitating intranuclear localization according to claim 28, wherein a long diameter of the particulate associated body is 300nm to 50 μ m.

30. (currently amended) The preparation for facilitating intranuclear localization according to ~~any one of claims 25 to 29~~claim 25, which comprises a collagen in a range of 0.01 to 1.0% by weight.

31. (canceled)

32. (original) A method of gene conversion of a cell, which comprises contacting a composition comprising at least collagen and an oligonucleotide for gene conversion with a cell in a living body by oral, nasal, via lung, intraportal, intramuscular, subcutaneous, organ surface, intraorgan or transdermal administration.

33. (currently amended) A method of treating a ~~gene diseases~~genetic disease, which comprises converting a gene of a cell of a subject exhibiting a genetic disease by using the method as defined in of claim 32.

34. (new) The preparation according to claim 2, wherein collagen is water-soluble collagen.

35. (new) The preparation according to claim 34, wherein the water-soluble collagen is atelocollagen.